Biogen banks on government coverage to restart stalled Alzheimer's drug sales
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Goldman Sachs tech conference highlights AI spending outlook
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Biogen (BIIB) PT Lowered to $390 at Oppenheimer
October 20, 2021 6:05 PM EDTOppenheimer analyst Jay Olson lowered the price target on Biogen (NASDAQ: BIIB) to $390.00 (from $450.00) while maintaining an Outperform rating.
The analyst commented, "Bolstered by a 3Q top- and bottom-line beat, BIIB outlined a number of steps to support the Aduhelm launch but deferred... More
Biogen (BIIB) Stock Edges Higher on Strong Earnings, Sales of New Alzheimer Drug Just $300k
October 20, 2021 9:00 AM EDTBiogen (NASDAQ: BIIB) stock is up about 1.5% in pre-open Wednesday after the company reported better-than-expected Q3 EPS.
BIIB reported Q3 EPS of $4.77 to beat the analyst estimate of $4.11. Revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
As far as full-year guidance is concerned, Biogen projects FY2021 EPS of $18.85-$19.35, versus the consensus of $18.61.... More
Long-term Prospects for Biogen’s (BIIB) Aduhelm Remain Key Question - Analyst
October 20, 2021 8:21 AM EDTEarlier today, Biogen (NASDAQ: BIIB) reported Q3 results: EPS of $4.77, $0.66 better than the analyst estimate of $4.11; revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.
The company also updated its full-year guidance: EPS of $18.85-$19.35, versus the consensus of $18.61; FY2021... More
